Technologies – NAP

Tumor Targeted Superantigen (TTS)

Our technology is based on the observation that the immune system is far more efficient in killing bacteria than cancer cells. The TTS platform coats the tumor with superantigen, a bacterial derivative thereby eliciting an antibacterial immune response against the tumor, potentially even in patients who do not respond to current immunotherapy approaches. By binding bacterial determinants to the tumor surface, the technology effectively converts a weak antitumoral immune response to a durable, antibacterial one. TTS technology carries the potential to augment the effectiveness of checkpoint inhibitors and other anticancer approaches, including chemotherapy and CAR-T cell therapy.


NeoTX’s lead TTS lead molecule, naptumomab estafenatox (NAP), is currently being evaluated for advanced solid tumors. Additional drug candidates developed with the TTS platform have the potential to treat hematologic cancers and additional solid tumor indications such as glioblastoma.


Additionally, NeoTX is actively exploring in-licensing deals and partnerships that give the company access to new early-stage drugs that would be complementary to the TTS platform.

Naptumomab estafenatox

Naptumomab estafenatox (NAP), NeoTX’s lead TTS candidate,is currently in a Phase 1b clinical trial in collaboration with AstraZeneca for advanced and metastatic solid tumor indications. NAP was licensed from Active Biotech (NASDAQ STOCKHOLM: ACTI) in 2016. It is currently under preclinical and/or clinical investigation as a stand-alone monotherapy and in combination with other modalities, including chemotherapy, CAR-T cell therapy and checkpoint inhibitors.

NAP is directed against tumors expressing 5T4 antigen, which is present on many types of cancers, including the most frequent solid tumors.

 Previous clinical trials have found NAP to be well-tolerated and demonstrated promising  preliminary signals of efficacy. A Phase 1b clinical trial of NAP in combination with a checkpoint inhibitor is ongoing.

To learn more about the trial (NCT03983954), please visit